(Q53405410)

English

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maartje Wouters

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

E M Dijkgraaf

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

S J A M Santegoets

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

A K L Reyners

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

R Goedemans

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

G G Kenter

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

A R van Erkel

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

M I E van Poelgeest

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

H W Nijman

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

J J M van der Hoeven

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

M J P Welters

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

S H van der Burg

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

27 July 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

2141-2149

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216383%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

The immune system in the pathogenesis of ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Interleukin-6 as a therapeutic target in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Immunological aspects of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

"MIATA"-minimal information about T cell assays

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Immunological and inflammatory functions of the interleukin-1 family

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

New insights into IL-12-mediated tumor suppression.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV309

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53405410&oldid=1749510304"